Skip to main content

Aprepitant Capsules, Galantamine Tablets, Praziquantel Tablets, and <1092> The Dissolution Procedure: Development and Validation

Type of Posting: Notice of Intent to Revise
Posting Date: August 28, 2020
Targeted Official Date: TBD
Expert Committee: Various

In accordance with the Rules and Procedures of the Council of Experts, this is to provide notice that USP intends to revise the monographs and the General Chapter listed below:

  • Aprepitant Capsules, Dissolution Test 3
  • Galantamine Tablets, Dissolution Test 3
  • Praziquantel Tablets, Dissolution, For products for veterinary use
  • <1092> The Dissolution Procedure: Development and Validation, Section 1.4 Choosing Apparatus

Comments were received that the term “peak vessel” used in the monographs for these articles and in the General Chapter is a proprietary name for a particular supplier and should be replaced with the non-proprietary term “apex vessel.” This change has no substantive impact on the standards and is intended to be effectuated using an accelerated revision process. 

Should you have any questions, please contact Margareth R. C. Marques, Principal Scientific Liaison (